Form 8-K AMGEN INC For: Jul 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Amgen, Inc. (AMGN) Tops Q2 EPS by 30c
July 29, 2014 4:16 PM EDTAmgen, Inc. (NASDAQ: AMGN) reported Q2 EPS of $2.37, $0.30 better than the analyst estimate of $2.07. Revenue for the quarter came in at $5.18 billion versus the consensus estimate of $4.9 billion.
Highlights:
Total revenues increased 11 percent to $5,180 million, with 8 percent product sales growth driven by strong performance across the portfolio, particularly Enbrel® (etanercept), Kyprolis® (carfilzomib), Prolia®... More